PL2035581T3 - Kompozycja DNA przeciwko FAP - antygenowi zrębowemu nowotworu i sposoby jej stosowania - Google Patents

Kompozycja DNA przeciwko FAP - antygenowi zrębowemu nowotworu i sposoby jej stosowania

Info

Publication number
PL2035581T3
PL2035581T3 PL07796305T PL07796305T PL2035581T3 PL 2035581 T3 PL2035581 T3 PL 2035581T3 PL 07796305 T PL07796305 T PL 07796305T PL 07796305 T PL07796305 T PL 07796305T PL 2035581 T3 PL2035581 T3 PL 2035581T3
Authority
PL
Poland
Prior art keywords
methods
against tumor
composition against
dna composition
tumor stromal
Prior art date
Application number
PL07796305T
Other languages
English (en)
Inventor
Ralph A Reisfeld
Markus Loeffler
Jörg A Krüger
Andreas G Niethammer
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of PL2035581T3 publication Critical patent/PL2035581T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL07796305T 2006-06-21 2007-06-21 Kompozycja DNA przeciwko FAP - antygenowi zrębowemu nowotworu i sposoby jej stosowania PL2035581T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81531606P 2006-06-21 2006-06-21
EP07796305A EP2035581B1 (en) 2006-06-21 2007-06-21 Dna composition against tumor stromal antigen fap and methods of use thereof
PCT/US2007/014440 WO2007149518A2 (en) 2006-06-21 2007-06-21 Dna composition against tumor stromal antigen fap and methods of use thereof

Publications (1)

Publication Number Publication Date
PL2035581T3 true PL2035581T3 (pl) 2013-01-31

Family

ID=38834119

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07796305T PL2035581T3 (pl) 2006-06-21 2007-06-21 Kompozycja DNA przeciwko FAP - antygenowi zrębowemu nowotworu i sposoby jej stosowania

Country Status (10)

Country Link
US (1) US20090253778A1 (pl)
EP (1) EP2035581B1 (pl)
JP (1) JP2009541328A (pl)
CN (1) CN101506381B (pl)
CA (1) CA2657217A1 (pl)
DK (1) DK2035581T3 (pl)
ES (1) ES2393372T3 (pl)
PL (1) PL2035581T3 (pl)
PT (1) PT2035581E (pl)
WO (1) WO2007149518A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
RS63367B1 (sr) 2010-08-31 2022-07-29 Glaxosmithkline Biologicals Sa Pegilovani lipozomi za isporuku rnk koja kodira imunogen
ES2716243T3 (es) 2010-10-11 2019-06-11 Glaxosmithkline Biologicals Sa Plataformas de suministro de antígenos
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
PT2750707T (pt) * 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
AU2017330338A1 (en) * 2016-09-21 2019-05-02 The Trustees Of The University Of Pennsylvania Optimized synthetic consensus inmunogenic compositions targeting fibroblast activation protein
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN112402597B (zh) * 2020-11-26 2022-04-01 四川大学 一种fap修饰的类外泌体纳米囊泡肿瘤疫苗
WO2022165019A1 (en) 2021-01-27 2022-08-04 Georgetown University Fibroblast activation protein modulation to alter immune cell migration and tumor infiltration
CN114561387B (zh) * 2022-02-28 2023-08-15 北京大学现代农业研究院 花生启动子及其应用
CN118894923A (zh) * 2024-07-11 2024-11-05 北京鸿岑生物科技有限公司 一种tcr-t及其制备方法以及在制备治疗肿瘤药物的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767242A (en) * 1994-04-20 1998-06-16 Boehringer Ingelheim Int'l Gmbh Isolated dimeric fibroblast activation protein alpha, and uses thereof
US6846910B2 (en) * 1994-04-20 2005-01-25 Ludwig Institute For Cancer Research Isolated proteins containing portions of FAPα and other proteins
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
AU2002367377A1 (en) * 2001-12-26 2003-07-24 Sloan Kettering Institute For Cancer Research Dna immunization with libraries of minigenes encoding degenerate variants of major histocompatibility class i restricted epitopes
AU2003210719A1 (en) * 2002-01-28 2003-09-02 Sloan-Kettering Institute For Cancer Research Identification of mutant antigens with enhanced immunogenicity
CN1653080A (zh) * 2002-03-07 2005-08-10 路德维格癌症研究院 淋巴管和血管的内皮细胞基因
US8716254B2 (en) * 2003-03-24 2014-05-06 The Scripps Research Institute DNA vaccines against tumor growth and methods of use thereof
WO2006010517A2 (en) * 2004-07-29 2006-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)

Also Published As

Publication number Publication date
WO2007149518A3 (en) 2008-11-13
EP2035581B1 (en) 2012-09-26
EP2035581A2 (en) 2009-03-18
ES2393372T3 (es) 2012-12-20
CN101506381B (zh) 2012-09-05
CA2657217A1 (en) 2007-12-27
US20090253778A1 (en) 2009-10-08
EP2035581A4 (en) 2010-01-20
CN101506381A (zh) 2009-08-12
DK2035581T3 (da) 2012-10-08
PT2035581E (pt) 2012-12-06
WO2007149518A2 (en) 2007-12-27
JP2009541328A (ja) 2009-11-26

Similar Documents

Publication Publication Date Title
PL2035581T3 (pl) Kompozycja DNA przeciwko FAP - antygenowi zrębowemu nowotworu i sposoby jej stosowania
SI2029173T1 (sl) Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
LT2373691T (lt) Anti-fxi antikūnai ir jų panaudojimo būdai
IL219268A0 (en) Anti-cd79b antibodies and immunoconjugates and methods of use
PT2185719E (pt) Anticorpos anti-rantes e processos para a sua utilização
IL178593A (en) Specific antibodies of fcγriib and methods for their use
IL248723A0 (en) Specific antibodies against the bcr complex and methods of using them
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
IL210485A0 (en) Compositions and methods of use for therapeutic antibodies
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
IL211623A0 (en) Anti-notch2 antibodies and methods of use
SI2657253T1 (sl) Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
PT2099796E (pt) Compostos azaindolilo e métodos de utilização
IL202424A0 (en) Telomerase activating compounds and methods of use thereof
IL182943A0 (en) Ovr110 antibody compositions and methods of use
ZA200808017B (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IL190226A0 (en) Organometallic compounds and methods of use thereof
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
IL192564A0 (en) Composition and method of use thereof
ZA201004894B (en) Nuctraceutical composition and methods of use
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
SI1919951T1 (sl) Anti-tnf-alfa protitelesa in postopki za uporabo
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use
ZA201004893B (en) Nuctraceutical composition and methods of use
IL179420A0 (en) Compositions of ndv and methods of use thereof for treatment of cancer